日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling

针对晚期实体瘤,采用优化PARP抑制的肿瘤靶向拓扑异构酶I抑制剂递送:一项采用间隔给药方案的I期临床试验

Thomas, Anish; Takahashi, Nobuyuki; Oplustil O'Connor, Lenka; Redon, Christophe E; Mohindroo, Chirayu; Sciuto, Linda; Pongor, Lorinc; Schmidt, Keith T; Steinberg, Seth M; Aladjem, Mirit I; Figg, William Douglas; O'Connor, Mark J; Pommier, Yves

Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.

BRCA1 和 BRCA2 相关乳腺癌的新辅助 PARP 抑制剂治疗方案:PARTNER,一项随机 II/III 期试验

Abraham Jean E, O'Connor Lenka Oplustil, Grybowicz Louise, Alba Karen Pinilla, Dayimu Alimu, Demiris Nikolaos, Harvey Caron, Drewett Lynsey M, Lucey Rebecca, Fulton Alexander, Roberts Anne N, Worley Joanna R, Chhabra Ms Anita, Qian Wendi, Brown Jessica, Hardy Richard, Vallier Anne-Laure, Chan Steve, Cidon Maria Esther Una, Sherwin Elizabeth, Chakrabarti Amitabha, Sadler Claire, Barnes Jen, Persic Mojca, Smith Sarah, Raj Sanjay, Borley Annabel, Braybrooke Jeremy P, Staples Emma, Scott Lucy C, Palmer Cheryl A, Moody Margaret, Churn Mark J, Pilger Domenic, Zagnoli-Vieira Guido, Wijnhoven Paul W G, Mukesh Mukesh B, Roylance Rebecca R, Schouten Philip C, Levitt Nicola C, McAdam Karen, Armstrong Anne C, Copson Ellen R, McMurtry Emma, Galbraith Susan, Tischkowitz Marc, Provenzano Elena, O'Connor Mark J, Earl Helena M

Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells.

遗传证据表明,PARP1 捕获是 BRCA 突变癌细胞中 PARP 抑制剂疗效的驱动因素。

Ribeiro Jonathan, Hansen Kjetil, van Beek Lotte, Stubbs Christopher, Frigola Joan, Talbot Sara, Bentouati Sabrina, Hall James, Wijnhoven Paul W G, Armenia Josh, Schimpl Marianne, Forment Josep V, Albertella Mark R, O'Connor Mark J, Illuzzi Giuditta

The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study

DNA-PK抑制剂AZD7648单药或联合聚乙二醇化脂质体阿霉素治疗晚期癌症患者:一项首次人体I/IIa期研究的结果

Yap, Timothy A; LoRusso, Patricia; Miller, Rowan E; Kristeleit, Rebecca; Paulovich, Amanda G; McMorn, Stephen; Oplustil O'Connor, Lenka; Lombardi, Benedetta; Marco-Casanova, Paola; Gangl, Eric T; Patel, Bharat; O'Connor, Mark J; Dean, Emma; Zviezdin, Roman; Plummer, Ruth

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair.

雄激素受体抑制作用将 PARP 抑制剂在前列腺癌模型中的活性扩展到 BRCA 突变和同源重组修复缺陷之外。

Illuzzi Giuditta, Galbiati Alessandro, Staniszewska Anna D, Hanson Robert, Michaloglou Chrysiis, Cooke Sophie L, Uznańska Karolina, Białecka Maja, Solarczyk Kamil, Dev Harveer S, Massie Charlie E, Albertella Mark R, Leo Elisabetta, Forment Josep V, O'Connor Mark J

Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma.

基因组规模的规律成簇间隔短回文重复序列筛选发现核苷酸代谢是弥漫性大B细胞淋巴瘤中可操作的治疗弱点

Davies Nicholas, Francis Tegan, Oldreive Ceri, Azam Maria, Wilson Jordan, Byrd Philip J, Burley Megan, Sharma-Oates Archana, Keane Peter, Alatawi Sael, Higgs Martin R, Rudzki Zbigniew, Ibrahim Maha, Perry Tracey, Agathanggelou Angelo, Hewitt Anne-Marie, Smith Edward, Bonifer Constanze, O'Connor Mark, Forment Josep V, Murray Paul G, Fennell Eanna, Kelly Gemma, Chang Catherine, Stewart Grant S, Stankovic Tatjana, Kwok Marwan, Taylor Alexander Malcolm

Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial

阿达沃塞替联合奥拉帕尼治疗难治性实体瘤患者:一项开放标签、剂量探索和剂量扩展的 Ib 期试验

Hamilton, Erika P; Falchook, Gerald S; Wang, Judy S; Fu, Siqing; Oza, Amit M; Imedio, Esteban Rodrigo; Kumar, Sanjeev; Ottesen, Lone; Mugundu, Ganesh M; de Bruin, Elza C; O'Connor, Mark J; Jones, Suzanne F; Spigel, David R; Li, Bob T

The development of a new oral health patient reported outcome measure: the New South Wales public dental services approach

开发一种新的口腔健康患者报告结果指标:新南威尔士州公共牙科服务方法

Chen, Rebecca; Ajwani, Shilpi; Christian, Bradley; Phelan, Claire; Srinivas, Ravi; Kenny, Josephine; O'Connor, Mark; Clarke, Kara; Sohn, Woosung; Yaacoub, Albert

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib

ATR抑制剂AZD6738(Ceralasertib)作为单药疗法以及与化疗和PARP抑制剂奥拉帕尼联合使用均具有抗肿瘤活性。

Wilson, Zena; Odedra, Rajesh; Wallez, Yann; Wijnhoven, Paul W G; Hughes, Adina M; Gerrard, Joe; Jones, Gemma N; Bargh-Dawson, Hannah; Brown, Elaine; Young, Lucy A; O'Connor, Mark J; Lau, Alan

Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations

针对不同人群,开发和验证跨种族多基因2型糖尿病风险评分

Ge, Tian; Irvin, Marguerite R; Patki, Amit; Srinivasasainagendra, Vinodh; Lin, Yen-Feng; Tiwari, Hemant K; Armstrong, Nicole D; Benoit, Barbara; Chen, Chia-Yen; Choi, Karmel W; Cimino, James J; Davis, Brittney H; Dikilitas, Ozan; Etheridge, Bethany; Feng, Yen-Chen Anne; Gainer, Vivian; Huang, Hailiang; Jarvik, Gail P; Kachulis, Christopher; Kenny, Eimear E; Khan, Atlas; Kiryluk, Krzysztof; Kottyan, Leah; Kullo, Iftikhar J; Lange, Christoph; Lennon, Niall; Leong, Aaron; Malolepsza, Edyta; Miles, Ayme D; Murphy, Shawn; Namjou, Bahram; Narayan, Renuka; O'Connor, Mark J; Pacheco, Jennifer A; Perez, Emma; Rasmussen-Torvik, Laura J; Rosenthal, Elisabeth A; Schaid, Daniel; Stamou, Maria; Udler, Miriam S; Wei, Wei-Qi; Weiss, Scott T; Ng, Maggie C Y; Smoller, Jordan W; Lebo, Matthew S; Meigs, James B; Limdi, Nita A; Karlson, Elizabeth W